DKSH Expands Healthcare Own Brands Portfolio With Acquisition Of Roche’s Rocephin Antibiotic Brand, Which Generated About CHF 61M In 2025 Net Sales
DKSH has acquired the rights for Rocephin® from Roche across more than 80 markets. Following the acquisition of Meliane® from Bayer announced in July, this transaction is a further step in DKSH’s strategy to expand its
DKSH bought a medicine brand called Rocephin from Roche. This shows DKSH is building up its own medicine business in many countries.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.